Business Description
Kintor Pharmaceutical Ltd
ISIN : KYG5273B1077
Share Class Description:
HKSE:09939: Ordinary SharesTotal Employee Number:
123Compare
Compare
Traded in other countries / regions
09939.Hong KongKNTPF.USA Index Membership
Hong Kong Stock Connect IPO Date
2020-05-22Description
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.38 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.47 | |||||
Debt-to-EBITDA | -0.46 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -16.45 | |||||
Beneish M-Score | -1.06 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 47.1 | |||||
3-Year EPS without NRI Growth Rate | 47 | |||||
3-Year FCF Growth Rate | 47.7 | |||||
3-Year Book Growth Rate | -51.3 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.08 | |||||
9-Day RSI | 30.49 | |||||
14-Day RSI | 31.14 | |||||
3-1 Month Momentum % | -30.56 | |||||
6-1 Month Momentum % | -31.03 | |||||
12-1 Month Momentum % | -27.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.43 | |||||
Quick Ratio | 0.34 | |||||
Cash Ratio | 0.26 | |||||
Days Inventory | 85.14 | |||||
Days Sales Outstanding | 31.29 | |||||
Days Payable | 585.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.6 | |||||
Shareholder Yield % | 0.83 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 24.65 | |||||
Operating Margin % | -528.66 | |||||
Net Margin % | -610.77 | |||||
EBITDA Margin % | -581.49 | |||||
FCF Margin % | -520.36 | |||||
OCF Margin % | -518.11 | |||||
ROE % | -87.83 | |||||
ROA % | -48.73 | |||||
ROIC % | -41.68 | |||||
3-Year ROIIC % | -133.73 | |||||
ROC (Joel Greenblatt) % | -124.68 | |||||
ROCE % | -74.65 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 21.03 | |||||
PB Ratio | 3.81 | |||||
Price-to-Tangible-Book | 10.25 | |||||
EV-to-EBIT | -3.73 | |||||
EV-to-Forward-EBIT | 8.55 | |||||
EV-to-EBITDA | -3.9 | |||||
EV-to-Revenue | 22.68 | |||||
EV-to-Forward-Revenue | 1.98 | |||||
EV-to-FCF | -4.36 | |||||
Earnings Yield (Greenblatt) % | -26.81 | |||||
FCF Yield % | -24.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kintor Pharmaceutical Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 36.035 | ||
| EPS (TTM) (HK$) | -0.484 | ||
| Beta | 2.1665 | ||
| 3-Year Sharpe Ratio | -0.02 | ||
| 3-Year Sortino Ratio | -0.03 | ||
| Volatility % | 94.52 | ||
| 14-Day RSI | 31.14 | ||
| 14-Day ATR (HK$) | 0.109364 | ||
| 20-Day SMA (HK$) | 1.8145 | ||
| 12-1 Month Momentum % | -27.27 | ||
| 52-Week Range (HK$) | 1.61 - 4.7 | ||
| Shares Outstanding (Mil) | 468.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kintor Pharmaceutical Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kintor Pharmaceutical Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-28 | In 29 days | ||
| General meeting for 2025 | 2026-06-18 09:00 | 2.29 (-1.29%) | ||
| Annual report for 2025 | 2026-04-29 | 2.87 (-2.05%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 2.91 (+5.05%) | ||
| Second quarter earnings results for 2025 | 2025-08-28 | 2.19 (-9.13%) | ||
| General meeting for 2024 | 2025-06-10 09:00 | 1.53 (+5.52%) | ||
| Annual report for 2024 | 2025-04-29 | 1.15 (-1.71%) | ||
| Fourth quarter earnings results for 2024 | 2025-03-26 | 1.62 (-2.41%) | ||
| Second quarter earnings results for 2024 | 2024-08-26 | 0.93 (+0.00%) |
Show
Entries
Kintor Pharmaceutical Ltd Frequently Asked Questions
What is Kintor Pharmaceutical Ltd(HKSE:09939)'s stock price today?
The current price of HKSE:09939 is HK$1.64. The 52 week high of HKSE:09939 is HK$4.70 and 52 week low is HK$1.61.
When is next earnings date of Kintor Pharmaceutical Ltd(HKSE:09939)?
The next earnings date of Kintor Pharmaceutical Ltd(HKSE:09939) is 2026-08-28 Est..
Does Kintor Pharmaceutical Ltd(HKSE:09939) pay dividends? If so, how much?
Kintor Pharmaceutical Ltd(HKSE:09939) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Kintor Pharmaceutical Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers